Sugi Predict

Sugi Predict / Compounds / SCHEMBL508871

SCHEMBL508871

SCHEMBL508871

Cc1cc(CBr)ccc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.51
▸ TSHR P16473 4/20 0.50
▸ HSD17B10 Q99714 1/20 0.47
▸ NR3C1 P04150 1/20 0.46
▸ PGR P06401 1/20 0.46
▸ AR P10275 1/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ HPGD P15428 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11804042 0.85 LMNA (0.40) MAPTTSHRHSD17B10NR3C1PGR
SCHEMBL1620602 0.85 ALDH1A1 (0.55) MAPTTSHRHSD17B10CYP3A4HPGD
SCHEMBL13344094 0.83 MAPT (0.53) MAPTTSHRHSD17B10NR3C1PGR
SCHEMBL18138464 0.83 MAPT (0.53) MAPTTSHRHSD17B10NR3C1PGR
SCHEMBL1117240 0.82 TSHR (0.50) MAPTTSHRCYP3A4HPGDALDH1A1
SCHEMBL14938607 0.82 MAPT (0.57) MAPTTSHRHSD17B10NR3C1PGR
SCHEMBL550670 0.81 MAPT (0.51) MAPTTSHRHSD17B10NR3C1PGR
SCHEMBL713941 0.81 TSHR (0.54) MAPTTSHRHSD17B10NR3C1PGR
SCHEMBL10662837 0.81 MAPT (0.51) MAPTTSHRHSD17B10NR3C1PGR
SCHEMBL7988274 0.81 MAPT (0.51) MAPTTSHRHSD17B10NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606564-B2 Adenosine receptor antagonist compounds ILDONG PHARMACEUTICAL CO., LTD. (KR) 2026-04-21 — — US disclosed
EP-4676926-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS ThirtyFiveBio Limited (GB) 2026-01-14 — — EP disclosed
EP-4573094-A2 CDK2 INHIBITORS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
CN-116425756-B Adenosine receptor antagonist compounds and uses thereof 日东制药株式会社 2025-05-13 — — CN disclosed
CN-118047762-B Preparation method of rizatriptan EP impurity C 深圳菲斯生物科技有限公司 2024-12-06 — — CN disclosed
EP-3227270-B1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RES LAB (KR) 2024-11-13 — — EP disclosed
CN-114829363-B Adenosine receptor antagonist compounds 日东制药株式会社 2024-10-01 — — CN disclosed
WO-2024184650-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. ThirtyFiveBio Limited (GB) 2024-09-12 — — WO disclosed
US-20240190824-A1 INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION ONO PHARMACEUTICAL CO., LTD. (JP) 2024-06-13 — — US disclosed
US-20240174665-A1 CDK2 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-05-30 — — US disclosed
US-6271385-B1 FUNGICIDES (SUCH AS THOSE FOR USE IN FARMING AND HORTICULTURE). KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2001-08-07 — — US disclosed
EP-1020441-A1 N-HETEROCYCLIC METHYLPROPYLAMINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND GERMICIDES KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2000-07-19 — — EP disclosed
CN-1042421-C Acridine derivatives GLAXO LAB SA (FR) 1999-03-10 — — CN disclosed
EP-0569380-B1 ACRIDINE DERIVATIVES GLAXO LAB SA (FR) 1997-05-28 — — EP disclosed
US-5604237-A IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT LABORATOIRES GLAXO SA (FR) 1997-02-18 — — US disclosed
CN-1081181-A Acridine derivatives GLAXO LAB SA (FR) 1994-01-26 — — CN disclosed
EP-0569380-A1 ACRIDINE DERIVATIVES. GLAXO LAB SA (FR) 1993-11-18 — — EP disclosed
WO-1992012132-A1 ACRIDINE DERIVATIVES LABORATOIRES GLAXO S.A. (FR) 1992-07-23 — — WO disclosed
EP-0494623-A1 Acridine derivatives LABORATOIRES GLAXO SA (FR) 1992-07-15 — — EP disclosed
US-5091390-A Inhibit angiotensin II binding to receptors E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174665-A1 CDK2 INHIBITORS AND USES THEREOF CDK2, CDK20, CDK1 MAPT 2917/4885TSHR 4345/4885HSD17B10 3272/4885
US-20240190824-A1 INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION KCNJ11, KCNJ1, KCNJ2 MAPT 1620/4885TSHR 2804/4885HSD17B10 2741/4885
US-12606564-B2 Adenosine receptor antagonist compounds ADORA2A, ADORA1, ADORA2B MAPT 3225/4885TSHR 136/4885HSD17B10 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.